Sinovac Q1 results boosted by strong vaccine sales growth
HONG KONG – Growing domestic and international sales of vaccines buoyed strong growth for one of China's top biotechs, as reflected in its first quarter results for 2014. Beijing-based Sinovac Biotech Ltd. (NASDAQ:SVA) reported $13.5 million in sales, a jump of 34.8 percent from $10.1 million during the same period in 2013. Sinovac's shares lost 21 cents Thursday, to close at $6.06.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST